Cotización Pyxis Oncology - PYXS

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Último Precio

2.26

Postura de Compra

2.25

Postura de Venta

2.26

Volume Operado de la Acción

5,454,428

3.80 Rango del Día 4.31

1.35 Rango de 52 semanas 6.85

Capitalización de Mercado [m]

134.393M

Precio Anterior

4.16

Precio de Apertura

4.25

Hora

100

2.26

(formt)

Última hora de negociación

Volumen financiero

US$ 21,830,911

Precio Promedio Ponderado

4.0024

Volumen promedio (3 m)

549,427

Acciones en circulación

59,465,729

Rendimiento del Dividendo

Ratio Precio/Utilidad

-3.09

Beneficio por acción (BPA)

-1.24

turnover

Beneficio neto

-73.79M

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the ... Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

pyxisoncology.com

Sede

Wilmington, Delaware, USA

Fundado

Pyxis Oncology Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PYXS. The last closing price for Pyxis Oncology was US$4.16. Over the last year, Pyxis Oncology shares have traded in a share price range of US$ 1.35 to US$ 6.85.

Pyxis Oncology currently has 59,465,729 shares in issue. The market capitalisation of Pyxis Oncology is US$247.38 million. Pyxis Oncology has a price to earnings ratio (PE ratio) of -3.09.

Form 8-K - Current report

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and...

Form S-8 - Securities to be offered to employees in employee benefit plans

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Third Quarter 2024

- Preliminary data from the first-in-patient Phase 1 dose escalation trial of PYX-201 to be announced at upcoming virtual and in-person event in New York City on Wednesday, November 20, 2024, at...

Pyxis Oncology to Host In-Person (NYC) and Virtual Investor Event on Wednesday, November 20, 2024, to Present Preliminary Data from the Phase 1 Dose Escalation Trial of PYX-201

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	-2.49	-52.4210526316	4.75	5.5	1.92	749290	4.21898893	CS
4	-1.23	-35.2435530086	3.49	5.5	1.92	610407	4.13725139	CS
12	-1.4	-38.2513661202	3.66	5.5	1.92	549427	3.78923145	CS
26	-1.85	-45.0121654501	4.11	5.5	1.92	559578	3.59440314	CS
52	0.84	59.1549295775	1.42	6.85	1.35	578752	4.03719479	CS
156	-10.34	-82.0634920635	12.6	13.3	1.1	598082	3.97665579	CS
260	-16.74	-88.1052631579	19	19	1.1	586793	4.15708247	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
FBRXForte Biosciences Inc	US$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	279.33M
XCURExicure Inc	US$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	US$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	US$ 4.55 (-47.28%)	816.93k
QMMMQMMM Holdings Limited	US$ 0.713999 (-43.78%)	4.61M
XTKGX3 Holdings Company Ltd	US$ 0.0901 (-37.82%)	5.95M
PRFXPainReform Ltd	US$ 1.02 (-27.14%)	5.09M
GLEGlobal Engine Group Holding Ltd	US$ 3.81 (-26.59%)	230.23k
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.191 (17.39%)	662.68M
DBGIDigital Brands Group Inc	US$ 0.1345 (15.35%)	326.45M
NVDANVIDIA Corporation	US$ 145.89 (-0.76%)	309.57M
QSIQuantum Si Inc	US$ 1.39 (119.59%)	283.09M
SLXNSilexion Therapeutics Corporation	US$ 0.3495 (54.51%)	200.06M